Innocell + CpG 1018

**Innocell + CpG 1018** is an investigational combination therapy consisting of **Innocell** (a cell-based cancer immunotherapy derived from tumor cells, though precise formulation details are limited in public sources) combined with **CpG 1018**, a synthetic oligodeoxynucleotide that acts as a potent adjuvant by agonizing Toll-like receptor 9 (TLR9). CpG 1018 is a 22-mer class B CpG oligodeoxynucleotide with a phosphorothioate backbone, which enhances its stability and immunostimulatory activity. The combination is designed to boost both the innate and adaptive anti-tumor immune response, leveraging CpG 1018's capability to activate plasmacytoid dendritic cells and B cells, promote a Th1-biased immune environment, and thereby potentially enhance tumor antigen presentation and cytotoxic lymphocyte activation. CpG 1018 is developed and commercially produced by Dynavax Technologies and is approved as an adjuvant for certain vaccines, but its use in combination with Innocell is investigational and not approved for any indication as of the current data[1][5]. Clinical development status for the Innocell + CpG 1018 combination, including developers and indications, is not comprehensively documented in publicly available sources.